PACE-CME

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

Remaining questions on SGLT inhibition  CKD A review of new outcome trials
RestartResume
10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom - Online CME
  • Overview

    Prof Baigent discusses the key areas of uncertainty of treatment with SGLT2 inhibitors in patients with CKD and what ongoing trials will likely contribute to our understanding of this drug class.

  • Educational information

    This lecture was part of a CME accredited symposium: 'Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition' held at ERA-EDTA in Copenhagen, Denmark.

  • Faculty

    Professor Colin Baigent, MD is Director of the MRC Population Health Research Unit and Deputy Director of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford, where he is Professor of Epidemiology. He is an Honorary Consultant in Cardiovascular Epidemiology at the Oxford University Hospitals Foundation Trust.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free